Top-Line: Upadacitinib in Ulcerative Colitis Vodcast Survey

On behalf of the AbbVie Rheumatology team, we hope you found this vodcast both enjoyable and professionally beneficial.

We strive for continual improvement of our educational initiatives and value your feedback. Thank you for taking time to answer the questions below.

AbbVie Pty Ltd, Mascot NSW, Australia. ABBV-AU-00072-E. OCT 2022.

Question Title

* 1. Did this video podcast address your query on the benefit-risk profile of upadacitinib in ulcerative colitis?

Yes

Somewhat

No

Question Title

* 2. Overall, how would you rate this video podcast?

Excellent

Very Good

Good

Fair

Poor

Question Title

* 3. How relevant are the topics discussed by the panel to your clinical practice?

Very relevant

Somewhat relevant

Not relevant

Question Title

* 4. How important to your clinical practice are the learnings from this recording?

Very important

Somewhat important

Not important

Question Title

* 5. Would you recommend this video podcast to a colleague?

Yes

No

Question Title

* 6. OPTIONAL – If you have any other feedback, or suggestions regarding topics for future GRID medical education initiatives, please let us know!